心血管病免疫学治疗路在何方?  

The road of immunotherapy in cardiovascular diseases:Where does it lead to?

作　　者：廖玉华[1] 程翔[1] 袁璟[1] 

机构地区：[1]华中科技大学同济医学院附属协和医院心内科心血管病免疫实验室教育部生物靶向治疗重点实验室,武汉430022

出　　处：《临床心血管病杂志》2018年第1期1-4,共4页Journal of Clinical Cardiology

摘　　要：伴随着心血管病发病机制与免疫炎症反应的认识,随机多中心临床试验证实抗炎症因子、免疫调节、免疫吸附和拮抗自身抗心肌抗体等免疫学治疗,可以降低冠心病、心力衰竭、扩张型心肌病患者的患病率或(和)病死率,治疗性疫苗和单克隆抗体将成为血脂异常和高血压长期防治的新途径。Immunotherapy for cardiovascular diseases has progressed apparently over the past decade,accompanied by the understanding of immuno-inflammatory response in the pathogenesis of these diseases.Several multicenter randomized clinical trials demonstrated that anti-inflammatory cytokine therapy,immunoregulation,and immunoadsorption or blocking anti-heart autoantibodies（AHA）could seperately benefit patients with coronary heart disease（CHD）,heart failure（HF）or dilated cardiomyopathy（DCM）by reducing their morbidities and/or mortalities.Based on these studies,therapeutic vaccines and monoclonal antibodies are indicated to be the most promising options for long-term prevention and treatment of the hyperlipemia and hypertension patients in the future.

关 键 词：心血管病 免疫学治疗 炎症因子 单克隆抗体 疫苗 

分 类 号：R542.2[医药卫生—心血管疾病]